toxiferine and Bronchial-Spasm

A multicentre prospective surveillance study was undertaken to compare the incidence and severity of adverse reactions attributed to atracurium and alcuronium. Clinical manifestations were used by the anaesthetist to diagnose an adverse reaction (a cutaneous reaction, a greater than 20% change in arterial pressure or heart rate, and bronchospasm). Of the 1956 patients receiving atracurium, 10.1% had adverse reactions compared with 17.9% of the 1425 patients receiving alcuronium (P less than 0.001). There were no longterm sequelae. The atracurium group had a markedly lower incidence of hypotension (3.4% v. 13.7%; P less than 0.0001), but a higher incidence of cutaneous reactions (4.6% v. 2.3%; P less than 0.005) which were not associated with other adverse reactions. There was a low incidence of bronchospasm in both groups (0.2% v. 0.1%).

Topics: Adult; Alcuronium; Atracurium; Bronchial Spasm; Drug Eruptions; Female; Humans; Hypotension; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Toxiferine

An asthmatic patient developed intense bronchospasm immediately following the administration of alcuronium and d-tubocurarine in the same anaesthetic. Intradermal test was positive for both of these drugs but negative for thiopentone and suxamethonium, both of which were given prior to alcuronium. The differential diagnosis and the possible mechanism of the reaction are discussed.

Topics: Adult; Alcuronium; Asthma; Bronchial Spasm; Female; Humans; Intradermal Tests; Pregnancy; Pregnancy, Ectopic; Rupture; Toxiferine; Tubocurarine

Topics: Alcuronium; Alfaxalone Alfadolone Mixture; Bronchial Spasm; Humans; Hypotension; Toxiferine